World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
34479
World Ranking
11656
National Ranking
5978

Nizar M. Tannir publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Nizar M. Tannir sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 707 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Nizar M. Tannir D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Nizar M. Tannir sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Nizar M. Tannir is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans various domains within medicine, biochemistry, genetics, and molecular biology, with particular emphasis on pulmonary and respiratory medicine, oncology, molecular biology, cancer research, and surgery.

Their scientific contributions have covered a broad range of topics, notably in renal cell carcinoma treatment, renal and related cancers, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, bladder and urothelial cancer treatments, pancreatic and hepatic oncology research, and ferroptosis and cancer prognosis.

Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Cancer Research
  • The Oncologist
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts

Co-authors who have collaborated extensively with Nizar M. Tannir include:

  • Pavlos Msaouel
  • Amishi Y. Shah
  • Matthew T. Campbell
  • Jianjun Gao
  • Eric Jonasch

Among recent scientific papers authored or co-authored by Nizar M. Tannir are:

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial, 2020, ESMO Open
  • Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial, 2020, Cancer
  • Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma, 2022, Cancer
  • Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02), 2020, Cancer Discovery
  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial, 2020, Journal for ImmunoTherapy of Cancer

Best Publications

  • Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

    Robert J Motzer;Nizar M Tannir;David F McDermott;Osvaldo Arén Frontera

  • Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

    Nicole M. Kuderer;Toni K. Choueiri;Dimpy P. Shah;Yu Shyr

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

  • Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.

    Laurence Albiges;Nizar M. Tannir;Mauricio Burotto;David McDermott;David McDermott

  • Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

    Ana M. Aparicio;Andrea L. Harzstark;Paul G. Corn;Sijin Wen;Sijin Wen

  • Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer

    Sriram Yennurajalingam;Susan Frisbee-Hume;J. Lynn Palmer;Marvin O. Delgado-Guay

  • Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

    Lijun Zhou;Xian-De Liu;Mianen Sun;Xuesong Zhang

  • Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma.

    Michael B. Atkins;Nizar M. Tannir

  • Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial

    Nizar M. Tannir;Eric Jonasch;Laurence Albiges;Emre Altinmakas

  • Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.

    Aarif Y. Khakoo;Christos M. Kassiotis;Nizar M Tannir;Juan Carlos Plana

  • Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

    Omar Mamlouk;Umut Selamet;Shana Machado;Maen Abdelrahim

  • Renal cell carcinoma: diagnosis, staging, and surveillance.

    Chaan S. Ng;Christopher G. Wood;Paul M. Silverman;Nizar M. Tannir

  • Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy

    Stephen H. Culp;Nizar M. Tannir;E. Jason Abel;Vitaly Margulis

  • Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.

    Robert J. Motzer;Bernard Escudier;Saby George;Hans J. Hammers

  • Patient survival after surgery for osseous metastases from renal cell carcinoma.

    Patrick P. Lin;Attiqa N. Mirza;Valerae O. Lewis;Christopher P. Cannon

  • Depressive Symptoms and Cortisol Rhythmicity Predict Survival in Patients with Renal Cell Carcinoma: Role of Inflammatory Signaling

    Lorenzo Cohen;Steven W. Cole;Anil K. Sood;Sarah Prinsloo

  • Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

    Robert J. Motzer;Bernard Escudier;David F. McDermott;Osvaldo Arén Frontera

  • Landscape of DNA Virus Associations across Human Malignant Cancers: Analysis of 3,775 Cases Using RNA-Seq

    Joseph D. Khoury;Nizar M. Tannir;Michelle D. Williams;Yunxin Chen

Frequent Co-Authors

Eric Jonasch
Eric Jonasch The University of Texas MD Anderson Cancer Center
Christopher G. Wood
Christopher G. Wood The University of Texas MD Anderson Cancer Center
Surena F. Matin
Surena F. Matin The University of Texas MD Anderson Cancer Center
Pheroze Tamboli
Pheroze Tamboli The University of Texas MD Anderson Cancer Center
Toni K. Choueiri
Toni K. Choueiri Harvard University
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Thomas Powles
Thomas Powles Queen Mary University of London
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Xiaoping Su
Xiaoping Su The University of Texas MD Anderson Cancer Center
Bernard Escudier
Bernard Escudier Institut Gustave Roussy

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in pursuing a medical career but aren't committed to a traditional MD path, there are several rewarding alternatives available through online study. Many students are now considering health administration roles, which are in high demand as healthcare systems grow more complex. For those wanting to lead in healthcare organizations, exploring the best online mha programs can open doors to managerial and executive roles.

Cost is often a major concern. Learners can find the cheapest online master degree in healthcare administration to keep their studies affordable without sacrificing quality or accreditation.

For nurses aiming for the top clinical roles, affordable doctoral programs are available. The most affordable dnp programs prepare practitioners for advanced practice and leadership positions in healthcare settings.

Aspiring pharmacists can also benefit from flexible online options. Consider enrolling in accredited online pharmacy programs to kickstart your pharmaceutical career and respond to growing community health needs.

Best Scientists Citing Nizar M. Tannir

Trending Scientists

Recently Published Articles